KIOVIG (human immunoglobulin): Reviews and patient testimonials

KIOVIG 100 mg/ml solution for infusion

Replacement therapy in adults, and children and adolescents (0-18 years) in:

• Primary immunodeficiency syndromes with impaired antibody production.

• Hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic leukaemia, in whom prophylactic antibiotics have failed.

• Hypogammaglobulinaemia and recurrent bacterial infections in plateau phase multiple myeloma patients who have failed to respond to pneumococcal immunisation.

• Hypogammaglobulinaemia in patients after allogeneic haematopoietic stem cell transplantation (HSCT).

• Congenital AIDS and recurrent bacterial infections.

Immunomodulation in adults, and children and adolescents (0-18 years) in:

• Primary immune thrombocytopenia (ITP), in patients at high risk of bleeding or prior to surgery to correct the platelet count.

• Guillain Barré syndrome.

• Kawasaki disease.

• Multifocal Motor Neuropathy (MMN).
Route of administration: Injectable
Molecule: human immunoglobulin